Coherus stockholders elect directors, approve say-on-pay and equity plan amendment

Coherus Oncology, Inc.

Elected Class I directors: Newcomer (48.3M for), Newton (47.2M for), Tzoumakas (46.1M for).
Ratified Ernst & Young as auditor for FY2024 with 79.8M for, 552K against.
Advisory say-on-pay approved (40.3M for, 16.5M against, 1.8M abstain).
Restated 2014 Equity Incentive Award Plan approved (37.6M for, 18.9M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.